跳至主要内容
临床试验/DRKS00010502
DRKS00010502招募中不适用

Effects of antihypertensive therapy on pregnancy outcome – An observational cohort study of the Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin

Pharmakovigilanz- und Beratungszentrum Embryonaltoxikologie0 个研究点目标入组 5,500 人开始时间: 2016年5月20日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
5,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
Female

入选标准

  • prospectively ascertained pregnancy

排除标准

  • Exclusion of concomitant therapy with known teratogens or fetotoxic drugs: carbamazepine, lenalidomide, methotrexate,mycophenolate, phenobarbital, phenytoin, retinoids, thalidomide, topiramate, valproate, ARBs (AT1-antagonists)* and ACE-inhibitors*. In addition malignant diseases are defined as exclusion criterion.
  • Therapy with ARBs (AT1-antagonists) and ACE-inhibitors* in the first trimester is only possible in the corresponding study groups of these substances, but pregnancies with continued therapy after week 20 are excluded.

研究者

发起方
Pharmakovigilanz- und Beratungszentrum Embryonaltoxikologie

相似试验